Efficacy of naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia prospective randomized controlled study to compare differences in efficacy between morning and evening medication

Efficacy of naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia : prospective randomized controlled study to compare differences in efficacy between morning and evening medication

A total of 100 patients with benign prostatic hyperplasia (BPH) and overactive bladder (OAB) symptoms (BPH/OAB), enrolled between June 2006 to March 2008, were randomly divided into 2 groups of morning medication (M) and evening medication (E) groups, then 50 mg of naftopidil was given once a day af...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Hinyokika kiyo. Acta urologica Japonica. - 1962. - 57(2011), 1 vom: 08. Jan., Seite 7-13
1. Verfasser: Sakai, Hideki (VerfasserIn)
Weitere Verfasser: Igawa, Tsukasa, Onita, Toru, Furukawa, Masataka, Hakariya, Tomoaki, Hayashi, Mikio, Matsuya, Fukuzo, Shida, Yohei, Nishimura, Naoki, Yogi, Yasuo, Tsurusaki, Toshifumi, Takehara, Kousuke, Nomata, Koichiro, Shiraishi, Kazutaka, Shono, Takefumi, Aoki, Daiyu, Kanetake, Hiroshi
Format: Aufsatz
Sprache:Japanese
Veröffentlicht: 2011
Zugriff auf das übergeordnete Werk:Hinyokika kiyo. Acta urologica Japonica
Schlagworte:Comparative Study English Abstract Journal Article Randomized Controlled Trial Adrenergic alpha-Antagonists Naphthalenes Piperazines naftopidil R9PHW59SFN
Beschreibung
Zusammenfassung:A total of 100 patients with benign prostatic hyperplasia (BPH) and overactive bladder (OAB) symptoms (BPH/OAB), enrolled between June 2006 to March 2008, were randomly divided into 2 groups of morning medication (M) and evening medication (E) groups, then 50 mg of naftopidil was given once a day after breakfast or supper for 8 weeks. Data were available for efficacy analysis on 80 patients (M group ; 43, E group ; 37). Naftopidil significantly improved the overall international prostatic symptom score ; from 19.2±7.9 to 11.7±5.8 in the M group and from 19.4±6.4 to 12.3±6.8 in the E group (p<0.0001), QOL score from 4.9±0.8 to 3.2±1.4 in the M group and from 5.0±0.8 to 3.6±1.3 in the E group (p<0.0001), and OAB symptom score from 7.8±2.6 to 5.0±2.5 in the M group (p<0.0001) and from 8.6±2.9 to 5.8± 3.3 in the E group (p<0.0001). There was no significant difference in the incidence of adverse effects between the M group (6.1%) and E group (2.2%). These results suggest that naftopidil improves storage symptoms as well as voiding symptoms regardless of timing of administration
Beschreibung:Date Completed 26.04.2011
Date Revised 15.11.2012
published: Print
Citation Status MEDLINE
ISSN:0018-1994